Spanish biotech developing peptide shuttle therapies to cross the blood-brain barrier for paediatric and adult brain tumours.
| Date | Round | Amount |
|---|---|---|
| Jun 2026 | Funding round Barcelona-based Gate2Brain secured a 7 million euro investment for a 30.4 percent equity stake from Shilpa Biocare, forming a strategic partnership to advance its lead brain tumour candidate. | $7.6M |
Tap an investor to see what else they have backed.
Data is community-curated and may be incomplete.